Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Fundamental Home Machines: An Easy to understand Determination Guide05.06.2024 - 2Falcon 9 rocket launches Starlink satellites before making 550th SpaceX landing (video)13.12.2025
- 35 Morning Schedules That Stimulate Your Day01.01.1
- 4US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes21.11.2025
- 5From School Dropout to Example of overcoming adversity: My Excursion22.09.2023
- Figure out How to Back Your Rooftop Substitution
- 7 Espresso Machines for Home Baristas
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- Find Wonderful Stream Voyage Objections On the planet
- Vote in favor of your Favored sort of footwear
- Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how
- Vote In favor of Your Favored Language Learning Applications
- Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- Los Angeles County sees significant uptick in norovirus cases, officials say
